Get the Stockscreener App
4.25
4.06%
-0.18
After Hours:
4.26
0.010
+0.24%
Entero Therapeutics Inc stock is traded at $4.25, with a volume of 43,860.
It is down -4.06% in the last 24 hours and down -15.00% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$4.43
Open:
$4.42
24h Volume:
43,860
Relative Volume:
0.02
Market Cap:
$6.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.20%
1M Performance:
-15.00%
6M Performance:
+315.81%
1Y Performance:
+121.35%
1-Day Range:
$4.15
$4.49
1-Week Range:
$3.7801
$4.5677
52-Week Range:
$0.9693
$5.84
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
4.25 | 9.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Institutional scanner results for Entero Therapeutics Inc.2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com
Entero Therapeutics Inc Stock Analysis and ForecastCandlestick Trading Patterns & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Will Entero Therapeutics Inc. stock recover after recent dropBond Market & AI Powered Market Trend Analysis - newser.com
Short interest data insights for Entero Therapeutics Inc.Weekly Stock Summary & Smart Money Movement Alerts - newser.com
Entero Regains Nasdaq Compliance With Grid AI Acquisition - Florida Today
Entero Therapeutics Regains Nasdaq Compliance After Extension - TipRanks
Entero Therapeutics Regains Nasdaq Compliance - TradingView
Nasdaq confirms ENTO equity-rule compliance; next filing crucial - Stock Titan
Published on: 2025-10-31 04:45:42 - newser.com
Why analysts remain bullish on Entero Therapeutics Inc. stockSwing Trade & Advanced Technical Analysis Signals - newser.com
Using economic indicators to assess Entero Therapeutics Inc. potentialJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Published on: 2025-10-31 00:01:01 - newser.com
Grid AI Corp. completed the acquisition of Entero Therapeutics, Inc. in a reverse merger transaction. - MarketScreener
Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO) - ACCESS Newswire
Entero (NASDAQ: ENTO) acquires GRID AI, adds $50M+ grid tech and Nasdaq compliance - Stock Titan
Entero Therapeutics (NASDAQ: ENTO) acquires 100% of Grid AI, regains Nasdaq compliance - Stock Titan
Entero Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Review & Weekly Stock Performance Updates - newser.com
Using data filters to optimize entry into Entero Therapeutics Inc.July 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Why Entero Therapeutics Inc. stock remains a top recommendationJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
Published on: 2025-10-29 01:24:51 - fcp.pa.gov.br
Why Entero Therapeutics Inc. stock is favored by top institutionsJuly 2025 Chart Watch & Advanced Technical Signal Analysis - fcp.pa.gov.br
Comparing Entero Therapeutics Inc. in custom built stock radarsMarket Rally & Consistent Growth Equity Picks - newser.com
Will Entero Therapeutics Inc. stock maintain dividend yieldJuly 2025 Update & Consistent Profit Trade Alerts - fcp.pa.gov.br
Published on: 2025-10-26 20:47:42 - newser.com
Published on: 2025-10-26 15:21:24 - newser.com
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):